Rep Plasmid Ratio Control for High-Titer Potent rAAV Vectors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant adeno-associated viral vectors (rAAVs) face challenges in achieving high titers of functional particles, with issues such as low production efficiency, cytotoxicity from long rep proteins, and high levels of empty capsids, which affect transduction efficiency and potency.
Innovation Solution
A rep plasmid system is developed with a controlled ratio of long to short adeno-associated virus replication proteins (1:5 to 1:5000) and heterologous elements, optimizing rAAV production to increase full capsids and viral genome titers, reducing cytotoxicity, and enhancing transduction efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If long rep proteins are produced at high levels, then viral genome replication is enhanced, but cytotoxicity increases and cell viability decreases
Solution Approach 1:
The patent changes the expression ratio parameter of rep proteins by using a heterologous element (such as a woodchuck post-transcriptional element or specific 3' UTR sequences) to preferentially enhance the expression of short rep proteins (rep40, rep52) over long rep proteins (rep78, rep68). This results in a controlled ratio where short rep proteins are expressed at higher levels than long rep proteins, achieving effective viral genome replication while reducing the cytotoxic effects associated with excessive long rep protein expression.
2Productivity
If conventional rep plasmid systems are used, then rAAV production is achieved, but the ratio of long to short rep proteins is uncontrolled leading to low full capsid formation
Solution Approach 1:
The patent introduces heterologous post-transcriptional elements (such as WPRE, β-globin 3' UTR, or specific polyadenylation signals) that differentially regulate the expression levels of long and short rep proteins. These elements preferentially enhance the stability and translation of short rep protein mRNAs, creating an optimized expression ratio that promotes efficient full capsid formation and packaging while maintaining overall rAAV production levels.
3Productivity
If high levels of long rep proteins are expressed, then viral replication capacity is increased, but transduction efficiency decreases due to cell death
Solution Approach 1:
The patent optimizes the expression ratio parameter by using heterologous post-transcriptional elements that preferentially enhance short rep protein expression. This creates a balanced profile where sufficient long rep proteins are present to support viral genome replication and packaging, while the reduced relative levels of long rep proteins minimize cytotoxicity and maintain cell viability, thereby preserving transduction efficiency.
4Quantity of substance
If standard AAV production methods are used, then viral particles are produced, but empty capsid levels are high reducing potency
Solution Approach 1:
The patent changes the stoichiometric ratio parameter of rep proteins by implementing heterologous post-transcriptional elements that preferentially enhance short rep protein expression. This optimized ratio (with short rep proteins expressed at higher levels) improves the efficiency of viral genome packaging into capsids, reducing the formation of empty capsids and increasing the proportion of full, potent viral particles while maintaining overall production levels.
Data Source
Figure 1a~1b
Figure 2
Figure 3
AI summary
The present invention relates to a rep plasmid comprising at least one long adeno-associated virus replication protein coding sequence encoding at least one long functional rep protein, at least one short adeno-associated virus replication protein coding sequence encoding at least one short functional rep protein, and at least one heterologous element, wherein following transcription the at least one heterologous element results in a ratio of long adeno-associated virus rep mRNA to short adeno-associated virus rep mRNA of about 1:5 to about 1:5000.